Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New vaccine shows promise for COPD patients at risk for pneumonia

10.09.2009
A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of the Respiratory and Critical Care Journal, a publication of the American Thoracic Society.

Because pneumonia disproportionately affects patients with COPD and frequently causes exacerbations, the Centers for Disease Control currently recommend that all adults with COPD receive the 23-valent pneumococcal polysaccharide vaccination (PPSV23). However, the efficacy of PPSV23 is not well established in the COPD patient population.

"Reasonable effectiveness for this vaccine has been demonstrated in cohort studies in adults with lung disease," said Mark Dransfield, M.D. of the University of Alabama at Birmingham and lead author of the study. "[However,] debate remains about its immunogenicity and effectiveness in COPD."

Dr. Dransfield and colleagues sought to determine the efficacy of a newer type of vaccine, PCV7, a protein conjugate vaccine, which attaches a weak antigen (in this case, the pneumococcal polysaccharide antigen) to a stronger antigen (the diphtheria toxin) in the hope that the stronger antigen with provoke a more forceful defense from the immune system.

"Conjugated vaccines were originally intended for young children who respond poorly to polysaccharide antigens," said Dr. Dransfield. "We wanted to see whether they could have a similar effect in the COPD patient population in whom immune responses may also be blunted."

Results of the randomized open label trial of 120 adults with moderate to severe COPD showed that, while both the PPSV23 vaccine and the PCV7 vaccine were well-tolerated, the PCV7 vaccine produced superior immune responses on several measures of immunogenicity. Among patients randomized to take the PCV7 vaccine, the fraction exhibiting a twofold increase in serotype-specific IgG antibodies was higher in five of the seven serotypes tested. Blood drawn from patients who had received the PCV7 vaccine was also more effective at killing pneumococci in six of seven serotypes tested one month after vaccination.

"We have shown that PCV7 induces a superior immune response to PPSV23 in COPD at one month post-vaccination," concluded Dr. Dransfield. "Both vaccines elicit responses comparable to those previous observed in health elderly patients." Older age and prior vaccination with PPSV23 dampened the efficacy of the PCV7 vaccine, however.

A vaccine in development that contains the capsule of 13 pneumococcal serotypes, called PCV13 (compared to PCV7 which has seven) is hoped to expand the coverage of the vaccine.

"We hope that future research will confirm the superior immunogenicity of PCV13 in COPD," he added. "We also want to determine the relative duration of the immune response following PPSV23 and conjugate vaccination and to identify the immunologic correlates of protection against both invasive and non-invasive pneumococcal disease. We believe our data provide the rationale for further study of the clinical efficacy of protein-conjugate pneumococcal vaccines in the high risk COPD population."

Keely Savoie | EurekAlert!
Further information:
http://www.thoracic.org

More articles from Health and Medicine:

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

nachricht Better equipped in the fight against lung cancer
16.05.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

Im Focus: Dozens of binaries from Milky Way's globular clusters could be detectable by LISA

Next-generation gravitational wave detector in space will complement LIGO on Earth

The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...

Im Focus: Entangled atoms shine in unison

A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.

The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

 
Latest News

Research reveals how order first appears in liquid crystals

23.05.2018 | Life Sciences

Space-like gravity weakens biochemical signals in muscle formation

23.05.2018 | Life Sciences

NIST puts the optical microscope under the microscope to achieve atomic accuracy

23.05.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>